History of Taiko Pharmaceutical's Seirogan, Seirogan Toi-A

In 1902, Mr. Saichi Nakajima began the manufactureing and sales of Chuyu-Seirogan in Osaka, In April 1946, Mr. Otojiro Shibata of Shibata Pharmacy (founded in Suita City, Osaka, in July 1940), forerunner of Taiko Pharmaceutical, has acquired Chuyu-Seirogan.
Chronicle of Taiko Pharmaceutical
              1946
              
                Nov 
Mr. Otojiro Shibata established Taiko Pharmaceutical Co., Ltd.in Suita City, Osaka, Japan, with a launch of CHUYU SEIROGAN (current SEIROGAN.)

              1954
              
                May
 Started the export of SEIROGAN to other countries.

              1964
              
                Apr 
The Tokyo Branch (current Tokyo Office) was established. 

              1966
              
                Oct
SEIROGAN TOI, a sugar coated tablet, was introduced to the market.

              1972
              
                Jun 
The headquarters and factory in Suita City, Osaka, were completed.

              1979
              
                Jun
The factory was remodelled to meet the GMP requirements. (*1). 

              1981
              
                Nov 
SEIROGAN TOI A, a sugar coated tablet, was introduced to the market.

              1990 
              
                Nov 
The Nagoya Branch (current Nagoya Office) was established. 

              1991 
              
                Nov 
The expansion of the factory and R&D building at the headquarters in Suita City, Osaka, was completed, including a well-equipped P3 Level laboratory in the R&D building.(*2). 

              1992 
              
                 Mar
Taiko Creosote Co., Ltd., (current Taiko TEC Co., Ltd.) was established in Suita City, Osaka, to produce wood creosote.

              1996 
              
                Dec 
Taiko Pharmaceutical Co., Ltd. (current Taiwan Branch) was established as an affiliate of Taiko Pharmaceutical Co.,Ltd.in Japan to strengthen sales in Taiwan.

              1997 
              
                Feb
The Shenzhen Oﬃce was established in China to conduct a market research and gather pharmaceutical information.

              2004 
              
                Nov 
Taiko Pharmaceutical (Asia Paciﬁc) Co., Ltd. was established, (now an aﬃliate of Taiko Pharmaceutical) for the sales and pharmaceutical businesses in Hong Kong and China.

              2005 
              
                Feb
Seirogan (International) Co., Ltd. was established in Hong Kong.

                Apr
Cleverin was introduced to the market.

                Nov
To promote the infection control business, Taiko Pharmaceutical Co.,Ltd. acquired the ownership of Abe Environmental Technologies (Shanghai) Co., Ltd., a sanitation control product manufacturer. As a consolidated subsidiary, the company changed its name to Taiko Abe Environmental Technologies (Shanghai) Co., Ltd. (the current consolidated subsidiary of Taiko Environmental Technologies (Shanghai) Co., Ltd.)

              2006
              
                Mar
Merged with Business Plan Inc to promote the infection control business

              2009
              
                Mar
Listed on the Tokyo Stock Exchange Market Second Section

              2010
              
                Apr
Listed on the Tokyo Stock Exchange Market First Section

              2011
              
                Aug
Acquired the exclusive domestic distribution rights for HIYAKIOGAN and commenced sales.

                Dec
The Tokyo Office was moved to new office.

              2012
              
                Feb
Established a branch office in Taiwan.

            *1. GMP -certified factory

                Good Manufacturing Practice (GMP) is a standard for maintaining the quality of pharmaceuticals during the manufacturing stage. In Japan, manufacturing facilities that comply with the manufacturing and quality-control standards stipulated by Ministry of Health, Labor and Welfare (MHLW) ordinance (Ministerial Ordinance on Standards for Manufacturing Control and Quality Control of Drugs, Quasi-drugs (MHLW Ordinance 179 of 24 December 2004)), which is based on the Pharmaceutical Affairs Law, are generally called “GMP-certified factory.”

                *2. P3 Level

                This is one of the “physical containment” levels designating facilities able to perform recombinant DNA testing. There are four levels, from P4 (strictest) to P1 (least strict), in accordance with the level of risk. Genetically modified organisms (GMOs) are “physically contained” in the research facility, in order to prevent them from being propagated or spread outside the facility or by the researchers. Research facilities and methods for conducting experiments are defined for each of these levels.